

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
31 March 2005 (31.03.2005)

PCT

(10) International Publication Number
WO 2005/028436 A3

(51) International Patent Classification⁷: **A61K 31/454**,
C07D 401/04, A61P 35/00, C07D 471/04, A61K 31/4439,
C07D 413/04, 211/88, 209/46, 209/44, A61K 31/4035,
31/45, 31/536, C07D 211/86, 211/84

(21) International Application Number:
PCT/US2004/030506

(22) International Filing Date:
17 September 2004 (17.09.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/504,724 17 September 2003 (17.09.2003) US

(71) Applicant (for all designated States except US): **THE GOVERNMENT OF UNITED STATES OF AMERICA**, as represented by **THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES** [US/US]; National Institutes of Health, Office of Technology Transfer, Suite 325, 6011 Executive Boulevard, Rockville, MD 20852-3804 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **GREIG, Nigel, H.** [US/US]; 11 Anne Brent Garth, Phoenix, MD 21131 (US). **HOLLOWAY, Harold** [US/US]; 121 Mariners Point Drive, Middle River, MD 21220 (US). **BROSSI, Arnold** [US/US]; 4877 Battery Lane, Apt. 1014, Bethesda, MD 20814 (US). **ZHU, Xiaoxiang** [CN/US]; 33 Palmetto Way, North Brunswick, NJ 08902 (US). **GIORDANO, Tony** [US/US]; 12341 Ellerbe Road, Shreveport, LA 71115 (US). **YU, Qian-sheng** [CN/US]; 116 Ridgely Road, Lutherville, MD 21093 (US). **FIGG, William, D.** [US/US]; 10451 Breckinridge Lane, Fairfax, VA 22030 (US).

(74) Agent: **REHMS, Aden, A.**; Klarquist Sparkman, LLP, One World Trade Center, Suite 1600, 121 SW Salmon Street, Portland, OR 97204 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:

— of inventorship (Rule 4.17(iv)) for US only

Published:

— with international search report
— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(88) Date of publication of the international search report:

19 May 2005

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: **THALIDOMIDE ANALOGS AS TNF-ALPHA MODULATORS**

(57) Abstract: Thalidomide analogs that modulate tumor necrosis factor alpha (TNF- α) activity and angiogenesis are disclosed. In particularly disclosed embodiments, the thalidomide analogs are isosteric sulfur-containing analogs. Also disclosed are methods of treating a subject with the analogs.



WO 2005/028436 A3